Comparison of Various Dosages of Escitalopram on Anxiety-like Behavior and Body Weight in Male Rats under Severe Chronic Stress Authors: Maryam Radahmadi, Zahra Farahbakhsh Published: 2025 ABSTRACT Background:Stress and escitalopram impact mood and various physiological systems. The present study aimed to compare the protective effects of different dosages of escitalopram on anxiety-like behavior and body weight in male rats subjected to severe chronic stress.Materials and Methods:Rats were randomly divided into groups: control, stress, sham, escitalopram (10 mg/kg and 20 mg/kg), and stress-escitalopram (10 mg/kg and 20 mg/kg). Restraint stress was induced 6h/day/14 days, and escitalopram was administered concurrently. The number of open arm entries (OAE%) and the total time spent in the open arms (OAT%) were assessed using the elevated plus maze test.Results:There were significant reductions in latency, OAT%, and OAE% within the stressed group. OAT% showed a notable increase in the Stress-Escitalopram10 and Stress-Escitalopram 20 groups when compared to the stressed group. Both OAT% and OAE% significantly decreased in the Stress-Escitalopram20 compared to the Stress-Escitalopram10. There were significant reductions in body weight differences across all experimental groups. The body weight in the Stress-Escitalopram20 was significantly lower than that of the group receiving only escitalopram at a dosage of 20 mg/kg.Conclusion:Escitalopram did not induce significant changes in anxiety-like behavior under stress-free conditions. The simultaneous administration of escitalopram, particularly at a dosage of 10 mg/kg, exhibited a protective effect in reversing of anxiety-like behavior under stressed conditions. Both doses of escitalopram resulted in a reduction of body weight in both stress and stress-free conditions, highlighting the dual behavioral and physiological effects of escitalopram. These findings offer novel insights into the dose-specific effects and potential side effects of escitalopram, thereby informing its clinical application for stress-related disorders. INTRODUCTION Anxiety disorders have a significant prevalence within the human population.[1] Furthermore, mental health and fluctuations in body weight are intricately related and have been shown to influence one another.[2] The development of anxiety-like behaviors and changes in body weight are affected by various factors, including a broad spectrum of psychological stressors, dysfunction of the serotonergic system, and abnormal regulation of the hypothalamic-pituitary-adrenal (HPA) axis.[34] Given these considerations, several treatment methods have been proposed to address mental disorders resulting from chronic stress and people’s quality of life.[5] It has been suggested that if chronic stress and anxiety are not effectively prevented or treated, they may lead to additional stress-related disorders, such as depression and other metabolic conditions (e.g., changes in body weight and obesity). Consequently, chronic stress can impose significant costs on society.[6] Selective serotonin reuptake inhibitors (SSRIs), such as escitalopram, are increasingly utilized for the treatment of chronic stress due to their milder and more tolerable side effects on behavior and other physiological systems.[7] Escitalopram has been reported to be widely used in the management of behavioral disorders, including stress, anxiety, and depression, as well as in changes in body weight.[89] There are differing opinions regarding the effects of escitalopram administration on body weight.[101112] Nevertheless, patients frequently experience weight fluctuations during SSRI treatment.[13] The aim is to better understand the dose-dependent effects of escitalopram on anxiety and its side effects on body weight in both stress and stress-free conditions, providing insights into optimal dosing strategies. Despite the extensive literature on the effects of escitalopram in mood disorders, there is currently no published report comparing the protective impact of two doses of escitalopram (10 mg/kg and 20 mg/kg) on anxiety-like behavior and body weight under severe chronic stress and stress-free conditions. Therefore, this study emphasizes the metabolic side effects of escitalopram and their relevance to real-world scenarios, where patients often experience weight fluctuations during SSRI treatment. MATERIALS AND METHODS Animals Forty-nine male Wistar rats, each weighing 200–250 g were obtained from Isfahan University of Medical Sciences. The rodents were housed in controlled environments with a temperature maintained at 22 ± 2°C, a light cycle from 7:00 to 19:00, and humidity levels kept at 50 ± 5%. Water and food were readily available, except during periods of stress. All testing involving the rats was approved by the Isfahan University of Medical Sciences Animal Use Ethics Committee in Iran (IR.MUI.MED.REC.1398.555). Following a 2-week adaptation period, the animals were randomly divided into seven groups (n = 7): the Control (Co) group, in which rats were kept in their cages; the Sham group, in which rats received only saline injections; the Stress group, in which rats were subjected to 6 hours of restraint stress each day; the Escitalopram 10 and 20 mg/kg (Esc10 and Esc20) groups, in which rats received escitalopram injections at doses of 10 and 20 mg/kg, respectively; and the Stress-Escitalopram 10 and 20 mg/kg (St-Esc10 and St-Esc20), in which the rats were exposed to stress and received escitalopram injections at a dose of 10 and 20 mg/kg; respectively, before the stress exposure. This procedure was repeated for 14 days for all experimental groups. Experimental procedure Medication Escitalopram oxalate was obtained in powder form from Sobhan Daru Co. in Iran. It was then solubilized in a saline solution to enable intraperitoneal (i.p.) administration at dosages of 10 and 20 mg/kg/day for 14 days before exposure to stress.[14] The usage of i.p. injection in the current study is a well-established method in animal research for preclinical studies and serves as a fundamental step toward understanding the mechanisms of action of the drug.[15] Indeed, i.p. injection is a common and effective method for ensuring rapid and predictable absorption, particularly when gastrointestinal conditions or oral routes may introduce variability.[15] Additionally, i.p. injection enables researchers to administer a precise dose with consistent absorption, allowing for reliable investigation of dose-response relationships and pharmacodynamics effects in preclinical studies. Stress induction In laboratory, rats are often exposed to various forms of stress based on type and duration.[16] In the present study, the severe stress model was induced by restraint stress which rats were confined in cylindrical restrainers for 6 h/day/14 days between 8:00 and 14:00.[17] Restraint stress is defined as a form of psychological stress[18] and serves as a potent emotional stress model in rodents[18] and serves as a potent emotional stress model in rodents.[19] Numerous studies have demonstrated that administering restraint for 2 to 8 hours daily for 14 days is sufficient to induce anxiety-like behaviors. Consequently, this 14-day duration is commonly employed in animal research to induce chronic stress.[20212223] Behavioral assessment The Elevated Plus Maze (EPM) test is widely employed to evaluate stress levels, anxiety-related behaviors, and the anxiolytic effects of pharmaceuticals.[2425] In the current study, an EPM apparatus was constructed from black, opaque Plexiglas and elevated 70 cm above the ground. The apparatus comprised two open arms, each measuring 60 cm in length, 10 cm in width, and 1 cm in height, as well as two closed arms, each measuring 60 cm in length, 10 cm in width, and 30 cm in height. These arms extended from a central platform, which measured 10 cm in length and 10 cm in width. On the 14th day, the animals were individually positioned at the center of the EPM apparatus, facing the open arms. Each animal was then allowed to freely navigate through various sections of the maze for 300 s.[2627] All movements were captured by a video recording device and subsequently analyzed. The number of open arm entries (OAEs) and the total time spent in the open arms (OAT) were recorded over a duration of 300 seconds, serving as criteria for assessing motor activity and anxiety in the EPM tests.[2728] The percentage of OAEs [OAE% = (OAE/Total entries to the open and closed arms) × 100] and the percentage of OAT [OAT% = (OAT/300) × 100] were calculated.[27] A significant increase in these two parameters indicates reduced anxiety in the animals.[29] Furthermore, the duration of time spent in the central zone was assessed to determine the animals’ place preference between the “safe” (peripheral) and “unsafe” (central) zones of the EPM. In addition, the latency time to enter the closed arms (i.e. the time taken to enter the closed arms, which indicates reduced anxiety) was measured to evaluate anxiety levels.[30] It is important to note that entering the open arm requires the animal to place all four legs within the open arm.[27] After each experiment, the entire apparatus was cleaned with 70% alcohol to prevent contamination in subsequent experiments.[30] Body weight differences Some studies have demonstrated that restraint stress affects body weight.[31] Additionally, the metabolic side effects of escitalopram and their relevance to real-world scenarios, where patients often experience weight fluctuations during SSRI treatment, are significant. Therefore, understanding these dose effects can help refine treatment strategies and prevent potential overmedication. Animal body weights were recorded at 8:00 a.m. on the first and 14th days of the experiment, respectively. The difference in weight between day 14 and day 1 was then calculated as the body weight difference (BWD = BW14 - BW1). Statistical analysis The data are presented as means ± standard error of the mean (SEM). All data were analyzed using one-way ANOVA, followed by a least significant difference (LSD) post hoc test. Statistical significance was determined by a P value of less than 0.05. The computations were performed using SPSS software version 26.0. RESULTS Since all EPM variables did not exhibit significant differences between the control (Co) and shock (Sh) groups, the control group was considered suitable as the reference for all subsequent comparisons [Figures 1-4]. (a) The percentage of time spent in the open arms (OAT%) during the EPM across various groups. Results are reported as means ± standard error of the mean (one-way ANOVA, followed by LSD post hoc test). **p < 0.01 compared to the Co group; ##p < 0.01 compared to the Sh group; θθθp < 0.001 compared to the St group; Ӿp < 0.05 compared to the St-Esc10 group. (b) Sample traces of the EPM tests for all experimental groups. Co: Control group, Sh: Sham group, St: Stress group, Esc10: Escitalopram 10 mg/kg/day, Esc20: Escitalopram 20 mg/kg/day, St-Esc10: Stress-Escitalopram 10 mg/kg/day, St-Esc20: Stress-Escitalopram 20 mg/kg/day The percentage of open arm entries (OAE%) during the EPM across various groups. Results are reported as means ± standard error of the mean (one-way ANOVA, followed by LSD post hoc test). *p < 0.05 compared to the Co group; #p < 0.05 compared to the Sh group; θp < 0.05 compared to the St group; ӾӾ P < 0.01 compared to the St-Esc10 group. Co: Control group, Sh: Sham group, St: Stress group, Esc10: Escitalopram 10 mg/kg/day, Esc20: Escitalopram 20 mg/kg/day, St-Esc10: Stress-Escitalopram 10 mg/kg/day, St-Esc20: Stress-Escitalopram 20 mg/kg/day The time spent in the center zone of the EPM test across various groups. Results are reported as means ± standard error of the mean (one-way ANOVA, followed by LSD post hoc test). Co: Control group, Sh: Sham group, St: Stress group, Esc10: Escitalopram 10 mg/kg/day, Esc20: Escitalopram 20 mg/kg/day, St-Esc10: Stress-Escitalopram 10 mg/kg/day, St-Esc20: Stress-Escitalopram 20 mg/kg/day The latency of entry into the closed arm in the EPM test across different groups. Results are reported as means ± standard error of the mean (one-way ANOVA, followed by LSD post-hoc test). *p < 0.05 compared to the Co group; #p < 0.05 compared to the Sh group; θp < 0.05 compared to the St group. Co: Control group, Sh: Sham group, St: Stress group, Esc10: Escitalopram 10 mg/kg/day, Esc20: Escitalopram 20 mg/kg/day, St-Esc10: Stress-Escitalopram 10 mg/kg/day, St-Esc20: Stress-Escitalopram 20 mg/kg/day Effect of escitalopram on EPM test The ANOVA assigned different levels of significance regarding the OAT% [F (6, 42) = 8.569, P = 0.000]. The OAT% significantly decreased (P < 0.01) in the St group compared to the Co group, indicating an increase in anxiety-like behavior as a result of chronic stress. Furthermore, the OAT% exhibited a significant enhancement (P < 0.01) in the St-Esc10 group compared to the Co group, suggesting that a dose of 10 mg/kg of escitalopram has a beneficial effect in reversing stress-induced anxiety [Figure 1]. OAT% was significantly higher in the St-Esc10 and St-Esc20 groups (both P < 0.001) compared to the St group [Figure 1], indicating the antianxiety effects of both doses of escitalopram under stress conditions. Furthermore, the OAT% was significantly lower in the St-Esc20 group (P < 0.05) compared to the St-Esc10 group, suggesting a reduced antianxiety effect of escitalopram at a dose of 20 mg/kg compared to a dose of 10 mg/kg during simultaneous exposure to stress and escitalopram [Figure 1]. The ANOVA assigned different levels of significance regarding the OAE% [F (6, 42) = 2.519, P = 0.036]. As illustrated in Figure 2, significant decreases in OAE% were observed in both the St and St-Esc20 groups when compared to the Co group (P < 0.05 for both). Additionally, the OAE% exhibited a significant enhancement (P < 0.05) only in the St-Esc10 group relative to the St group. Finally, the OAE% was significantly lower in the St-Esc20 group (P < 0.01) compared to the St-Esc10 group, indicating that escitalopram at a dosage of 20 mg/kg had a diminished protective effect in reversing anxiety-like behavior in subjects experiencing simultaneous stress. The ANOVA assigned different levels of significance regarding the time spent in the center zone [F (6, 42) = 0.813, P = 0.566]. The time spent in the center zone did not exhibit significant differences among the various experimental groups when compared to the Co group [Figure 3], indicating that there was no place preference across all experimental groups. However, the St-Esc10 group spent more time in the center zone (an unsafe location) than the other groups. The ANOVA assigned different levels of significance regarding the latency of entrance to the closed arm [F (6, 42) = 1.777, P = 0.127]. The latency to enter the closed arm significantly decreased (P < 0.05) in the St group compared to the Co group, indicating an increase in anxiety in this group. Furthermore, there were significant improvements in latency in the St-Esc10 and St-Esc20 groups (P < 0.05 for both) compared to the St group. This indicated antianxiety behavior resulting from both doses of escitalopram under stress conditions [Figure 4]. Effect of Escitalopram on body weight differences The ANOVA assigned different levels of significance regarding BWD [F (6, 42) = 12.051, P = 0.000]. The BWD exhibited significant reductions in all experimental groups when compared to the Co group (Co) (P < 0.001 for the St, Esc10, St-Esc10, and St-Esc20 groups, and P < 0.01 for the Esc20 group). Additionally, the BWD demonstrated a significant decrease (P < 0.05) in the St-Esc20 group compared to the Esc20 group [Figure 5]. Disparities in body weight among different groups. Results are reported as means ± standard error of the mean (one-way ANOVA, followed by LSD post-hoc test). **p < 0.01 and ***p < 0.001 compared to the Co group; ##p < 0.01 and ###p < 0.001 compared to the Sh group; ∆p < 0.05 compared to the Esc20 group. Co: Control group, Sh: Sham group, St: Stress group, Esc10: Escitalopram 10 mg/kg/day, Esc20: Escitalopram 20 mg/kg/day, St-Esc10: Stress-Escitalopram 10 mg/kg/day, St-Esc20: Stress-Escitalopram 20 mg/kg/day DISCUSSION The present study compared the protective effects of various doses of escitalopram on anxiety-like behavior and body weight in male rats subjected to severe chronic stress and those in stress-free conditions. According to the current findings, severe chronic stress (6h/day/14 days) increased anxiety-like behaviors in the subjects. It has been reported that elevated levels of anxiety and decreased motor activity are the most common conditions among the cluster of neurobehavioral disorders associated with chronic stress.[323334] Whereas another study reported that stress increases exploratory behavior, such as motor activity in rodents,[35] these differences may be attributed to factors such as methodology, age, gender, stress duration, and type.[31] Additional recent findings indicated that the administration of escitalopram at dosages of 10 and 20 mg/kg did not produce any significant changes in anxiety-like behavior under stress-free conditions. Another study reported that different doses of escitalopram (0.03, 0.1, or 0.3 mg/kg) did not impact anxiety-like behavior in the EPM test under stress-free conditions.[36] It appears that the higher doses of escitalopram in the present study exhibited a dose-dependent pattern in stress-free conditions. On the other hand, both doses of escitalopram, particularly the 10 mg/kg dose, reversed anxiety-like behavior under stress conditions even more than the control subjects. It appears that increased serotonin activity can alleviate anxiety symptoms by promoting a more relaxed and exploratory behavior.[37] In the present study, it seems that escitalopram at a dose of 10 mg/kg might be more effective under stress conditions, leading to improved behavioral performance. This response could be related to compensatory mechanisms in the central nervous system during stress conditions. In the Stress-Escitalopram10 subjects, stress might exhibit an augmented sensitivity to the medication.[38] Stress alters neurotransmitter systems, particularly serotonin, which could amplify the medication’s effects and enhance behavioral outcomes. Nevertheless, the 20 mg/kg dose of escitalopram demonstrated reduced efficacy compared to the 10 mg/kg dose in stressed subjects. This suggests that higher doses of escitalopram may result in desensitization or downregulation of serotonin receptors, such as 5-HT1A, which could lead to diminished anxiolytic effects in these subjects.[39] Other studies have reported that escitalopram injections at various doses (5, 10, and 20 mg/kg/day for 14 days) enhanced the antianxiety effects during periods of stress.[404142] It appears that different doses of escitalopram may operate through distinct pathways to reduce anxiety associated with elevated HPA activity.[43] However, it has also been reported that escitalopram at doses of 0.5 and 5 mg/kg did not alleviate anxiety-like behaviors.[404445] Various mechanisms may be proposed for the action of escitalopram, including alterations in the secretion of neurotransmitters (e.g., serotonin) and hormones e.g., corticosterone).[234146] Additionally, serotonin influences several brain regions, including the amygdala, prefrontal cortex, and hippocampus, which are essential for emotional processing and the regulation of anxiety.[474849] According to recent findings, severe chronic stress resulted in weight loss among all experimental subjects. Stress-induced weight loss is a common physiological response, particularly when stress is prolonged.[50] Chronic stress often leads to anorexia or reduced food intake,[51] which may be attributed to stress-induced elevations in corticosteroids (such as cortisol in humans or corticosterone in rodents) and possibly adrenaline.[52] A previous study confirmed elevated corticosterone levels induced by stress using a similar methodology.[14] Corticosterone alters appetite regulation, and prolonged exposure to high levels can lead to catabolic states, in which the body breaks down muscle and fat stores for energy.[5354] Various mechanisms have been implicated in the elevated anxiety-like behavior associated with chronic stress, including disruption of serotonin systems, reduction of serotonin receptor function, and impairment of serotonergic signaling.[55] Additionally, there is an enhancement of sympathetic nervous system activity and HPA axis for elevated anxiety,[5657] which can result in alterations in metabolism and appetite.[58] Furthermore, stress may increase thermogenesis, muscle tension, and metabolic rate, contributing to weight loss.[5960] Finally, anxiety-related behaviors, such as food avoidance, are common in stressed animals, further exacerbating weight reduction.[61] Based on existing findings, escitalopram has been shown to reduce body weight under both stressed and stress-free conditions, with a more pronounced effect observed in stressed conditions. Specifically, a dosage of 20 mg/kg of escitalopram resulted in greater weight loss in stressed individuals compared to administration of the same dosage in stress-free conditions. However, there are paradoxical findings regarding the impact of escitalopram on body weight. For instance, escitalopram led to a reduction in body weight in stress-free conditions after 60 days.[62] Additionally, oral escitalopram at a dosage of 10 mg/kg/day for 4 weeks also decreased body weight in stress-free conditions.[63] Conversely, it has been reported that oral escitalopram at dosages of 10 and 20 mg/kg did not significantly alter body weight after 30 days.[62] Furthermore, Montagnini et al. (2013)[64] suggested that escitalopram at doses of 2, 6, and 18 mg/kg for 3 days resulted in an increase in body weight in stress-free conditions. Escitalopram can modify serotonergic signaling in the brain, particularly in regions involved in the regulation of hunger and satiety, such as the hypothalamus.[65] Serotonin plays a crucial role in promoting satiety and decreasing food intake, and long-term use of SSRIs has been linked to reduced appetite and subsequent weight loss.[6667] Enhanced serotonergic signaling, particularly through the 5-HT2C receptor, promotes satiety, potentially leading to reduced food consumption and weight loss.[68] Furthermore, escitalopram may affect gut-brain signaling pathways,[68] resulting in alterations in digestive efficiency and food absorption, which could further facilitate the observed weight loss. On the other hand, escitalopram (26.5 mg/kg for 12 weeks) was associated with significant reductions in body weight under both stress-free and stressed conditions.[969] In contrast, escitalopram administered at doses of 2.5 and 10 mg/kg over 4 weeks did not significantly affect body weight in either stress or stress-free conditions.[101112] Furthermore, daily administration of escitalopram (20 mg/kg for 6 weeks) resulted in body weight gain in anxious mice.[70] Additionally, another study reported that stress therapy with escitalopram (10 mg/kg/day for 21 days) led to an increase in body weight under stress conditions.[4371] Nevertheless, there are several potential biological, behavioral, and pharmacological mechanisms regarding the role of the combination of escitalopram and stress in weight loss. Indeed, escitalopram is known to have mood-modulating effects that may lead to changes in feeding behavior.[65] For instance, reduced food-seeking behavior may result from the anxiolytic effects of escitalopram, particularly in the context of chronic stress. It appears that the stressed subjects in the present study may have consumed less food due to both reduced anxiety and increased serotonergic activity, both of which have been associated with decreased food intake in animal models. Consequently, elevated serotonin levels resulting from escitalopram treatment can lead to increased satiety and diminished hunger, contributing to lower food consumption and subsequent weight loss, potentially mediated by activated spexin as a potent anorexigenic factor. Moreover, the combination of chronic stress and escitalopram treatment likely results in an altered energy balance, where decreased food intake due to serotonergic effects on appetite is compounded by stress-induced metabolic changes.[72] The weight reduction observed in combination with stress and escitalopram suggests that escitalopram enhances the catabolic effects of stress, resulting in greater weight loss compared to control subjects. Furthermore, escitalopram may also affect the HPA axis, which plays a crucial role in the body’s response to stress and the regulation of energy homeostasis.[73] Overall, this paradoxical effect of escitalopram on body weight may be influenced by various biochemical factors (e.g., serotonin levels), as well as methodological differences, age, gender, duration, and type of stress.[747576] The novelty of the present study lies in its findings, which challenge the common assumption of linear dose–response relationships. Additionally, this research provides new insights into the metabolic side effects associated with both doses of escitalopram and how stress exacerbates these effects. Consequently, these findings offer valuable information regarding dose-specific effects and potential side effects of escitalopram, thereby informing its clinical application for stress-related disorders. The interplay between escitalopram treatment, chronic stress, and the observed anxiolytic effects and weight loss can be elucidated through several mechanisms that depend on the dosage of escitalopram. These mechanisms include serotonergic modulation, stress-induced metabolic changes, and neuroendocrine responses. Notably, the dose-dependent nature of weight reduction—evident with greater weight loss at 20 mg/kg—suggests a nonlinear effect of escitalopram. Higher doses may not only enhance its therapeutic effects but also amplify side effects, such as appetite suppression, or potentially induce further metabolic changes. Therefore, understanding the impact of varying doses of escitalopram is crucial for refining treatment strategies and preventing potential overmedication. More research is needed to confirm these findings and to further elucidate the complex mechanisms underlying the effects of escitalopram on stress-related outcomes, particularly at different dosage levels. CONCLUSION Escitalopram (10 and 20 mg/kg) did not induce significant changes in anxiety-like behavior under stress-free conditions. However, simultaneous administration of escitalopram, particularly at a dosage of 10 mg/kg, exhibited a reversing effect on the anxiety-like behavior under stressed conditions. Both doses of escitalopram resulted in reduced body weight in both stress and stress-free environments, underscoring the dual behavioral and physiological effects of escitalopram. These findings offer novel insights into the dose-specific effects and potential side effects of escitalopram, thereby informing its clinical application for stress-related disorders. The weight reduction observed in the St-Esc 10 and St-Esc 20 mg/kg groups appears to be attributable to a combination of pharmacological, biological, and behavioral factors, including (i) the appetite-suppressing effects of serotonin through alterations in central serotonin systems that regulate hunger and satiety; (ii) stress-induced physiological mechanisms, such as modified metabolic responses, increased energy expenditure, and changes in the HPA axis; and (iii) behavioral changes, such as decreased food intake resulting from reduced anxiety or alterations in feeding behavior. Ethics approval and consent to participate All the experimental procedures in this study were conducted in accordance with the Institutional Animal Care guidelines of Isfahan University of Medical Sciences and approved by the Research Ethics Committee of Isfahan, Iran (ethical code: IR.MUI.MED.REC.1398.555). Consent for publication All authors reviewed the results and approved the final version of the manuscript. Data availability statement Supporting data is available upon responsible request. Conflicts of interest There are no conflicts of interest.